このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Enveric Biosciences 将来の成長

Future 基準チェック /06

Enveric Biosciences の収益は、年間 21.3% 減少すると予測されています。EPS は、年間増加すると予測されています39.1%。

主要情報

-21.3%

収益成長率

39.1%

EPS成長率

Pharmaceuticals 収益成長	23.6%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	01 Aug 2024

今後の成長に関する最新情報

更新なし

Recent updates

An Intrinsic Calculation For Enveric Biosciences, Inc. (NASDAQ:ENVB) Suggests It's 40% Undervalued

Jul 02

業績と収益の成長予測

NasdaqCM:ENVB - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-21	N/A	N/A	1
12/31/2025	N/A	-20	N/A	N/A	1
12/31/2024	N/A	-18	N/A	N/A	1
6/30/2024	N/A	-11	-10	-10	N/A
3/31/2024	N/A	-15	-12	-12	N/A
12/31/2023	N/A	-17	-14	-14	N/A
9/30/2023	N/A	-23	-16	-16	N/A
6/30/2023	N/A	-23	-18	-18	N/A
3/31/2023	N/A	-19	-18	-18	N/A
12/31/2022	N/A	-19	-18	-17	N/A
9/30/2022	N/A	-52	-19	-18	N/A
6/30/2022	N/A	-52	-16	-15	N/A
3/31/2022	N/A	-50	-14	-13	N/A
12/31/2021	N/A	-49	-12	-11	N/A
9/30/2021	N/A	-11	-10	-10	N/A
6/30/2021	N/A	-9	-9	-8	N/A
3/31/2021	N/A	-9	-7	-6	N/A
12/31/2020	N/A	-7	-4	-4	N/A
9/30/2020	N/A	-3	-2	-2	N/A
6/30/2020	N/A	-3	-1	-1	N/A
3/31/2020	N/A	-3	-1	-1	N/A
12/31/2019	N/A	-2	-1	-1	N/A
9/30/2019	N/A	-3	-1	-1	N/A
12/31/2018	N/A	-2	-1	-1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ENVB今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ENVB今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ENVB今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ENVBの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: ENVB来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ENVBの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Enveric Biosciences 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

New major risk - Financial position

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to Be Dosed Orally

An Intrinsic Calculation For Enveric Biosciences, Inc. (NASDAQ:ENVB) Suggests It's 40% Undervalued

Enveric Biosciences Regains Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(b)(1)

Enveric Biosciences Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Marketplace Rule 5550(a)(2)

New major risk - Financial position

Enveric Biosciences, Inc., Annual General Meeting, May 28, 2024

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Enveric Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $0.322453 million.

New major risk - Share price stability

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Enveric Biosciences Receives Notice from the Nasdaq Stock Market

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

Enveric Biosciences Selects Development Candidates from Evm301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Enveric Biosciences Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373

Enveric Biosciences, Inc., Annual General Meeting, Nov 02, 2023

Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program

Enveric Biosciences, Inc. Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373

Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373

Enveric Biosciences, Inc. Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing

Enveric Biosciences, Inc. Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders

Enveric Biosciences, Inc. Receives Notice of Allowance from Uspto for Novel Prodrug of Psilocin

High number of new and inexperienced directors

Enveric Biosciences, Inc. Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling Studies

Enveric Biosciences, Inc., Annual General Meeting, Oct 28, 2022

Enveric Biosciences, Inc. Appoints Robert Dickey IV as Chief Financial Officer

Enveric Biosciences, Inc. Regains Compliance with Listing Rule 5550(a)(2) Letter from the Listing Qualifications Department of Nasdaq

Enveric Biosciences, Inc. Appoints New Independent Directors

Enveric Biosciences, Inc. announced that it expects to receive $5 million in funding

Enveric Biosciences to raise $8M in stock offering for corporate use

Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines

Enveric Biosciences, Inc. Announces Appointment of Frank Pasqualone to the Board of Directors

Enveric Biosciences Announces Management Appointments

High number of new and inexperienced directors

Enveric Biosciences, Inc. Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application

Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules

Enveric Biosciences, Inc. announces development of EV104a and EV104b

Enveric Biosciences Goes Psychedelic With MagicMed Acquisition

Enveric Biosciences, Inc. (NasdaqCM:ENVB) entered into a definitive agreement to acquire MagicMed Industries Inc.

Enveric Biosciences, Inc. announced delayed annual 10-K filing

Enveric Biosciences, Inc. Appoints Dr. Douglas D. Lind to Company's Board of Directors

Enveric Biosciences, Inc. (NasdaqCM:ENVB) completed the acquisition of Exclusive and perpetual license for Diverse Biotech novel molecules from Diverse Biotech, Inc.

Enveric Biosciences announces $10M registered direct offering

Enveric Biosciences Inc. Appoints Dr. Marcus Schabacker to Board of Directors

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘